Abstract: The invention relates to the use of a silicone oil emulsion comprising 0.01-85 wt. % of silicones, particularly polydimethylsiloxanes, 0.01-90 wt. % of hydrophobic emulsifier that has an HLB value ranging from 1 to 7 and/or a hydrophilic emulsifier that has an HLB value ranging from 7 to 14 and/or 0.01-90 wt. % of a mixture of one or more hydrophobic and hydrophilic emulsifiers having an HLB value ranging from 1 to 14, and 0.1-99 wt. % of biocompatible saline solution, for producing a medicament as such or in combination with other medicaments or carrier materials for treating septic infections triggered by bacterial, viral, parasitic, and fungal causative agents or diseases in animals and humans caused by traumas.

Abstract: The invention relates to a method for production of an oral, rectal or vaginal preparation comprising a solid silicone oil emulsion, characterized in that said preparation comprises 0.01-85 wt. % dimethicone and 0.01-45 wt. % dimethylsulphoxide, whereby the preparation dissolves after application and the emulsion is released. The dimethylsulphoxide is then resorbed and the remaining components of the preparation remain in the gut or vagina as a result of the molecular size thereof and subsequently are totally deposited. The invention further relates to a preparation and a method for production of a preparation made from a silicone oil emulsion.

Abstract: The invention concerns a process for treating systemic inflammatory response syndrome (SIRS), intensive care requiring conditions, viral diseases, Colitis ulcerosa, Crohn's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, infectious hospital polyresistance conditions of viral and bacterial sources (infections hospitalismus), bronchial asthma, kidney and urethral infections, migraines, rheumatoid arthritis, osteoporosis Sudeck, acute and chronic inflammations, venal and arterial inflammations, acute and chronic exhaustion conditions, tumors, muscle shrinkage diseases, hemorrhoids, chemically induced heart diseases, hypertonia, aging phenomena, acute and chronic pain conditions, spastics, polyneuropathies, prostate neoplasms, hair loss, impotence, neurodermitis, cervical syndrome, tissue traumas, and amyotropic lateral sclerosis (Lou Gehrig's disease), which comprises administering to a patient in need therefor an effective amount of Paravac composition which can suitab

Abstract: Adjuvants are disclosed for antigens such as viruses, bacteria and parasites, including their metabolic products or parts of the virus, bacteria and parasite structures for the immunization, as well as a process for producing such adjuvants and their uses. The object of the invention is to create adjuvants that in combination with vaccine antigens or with peptidoglycanes in histocompatible composition allow the defence mechanisms in the body to be stimulated to such a large extend that for the first time besides active immunoprophylaxis a even of weak antigens also a general and specific immunotherapy is made possible. The cost of producing the adjuvant should not exceed the usual cost and should ensure the applicability of the vaccine. In relatively weak immuno-incompetent phases of life, a combination of general immunoprophylaxis or the only use of the adjuvant should ensure a high immuno-competence. Residual effects of the adjuvant should not cause any problems.